Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Maxim Group Downgrades Palisade Bio to Hold

Maxim Group Downgrades Palisade Bio to Hold

Maxim Group analyst Naz Rahman downgrades Palisade Bio (NASDAQ:PALI) from Buy to Hold.

byBenzinga Newsdesk

August 19, 2022

1 minute read

Maxim Group analyst Naz Rahman downgrades Palisade Bio (NASDAQ:PALI) from Buy to Hold.

Analyst Ratings

Expert Ratings for Exact Sciences

By Benzinga Insights

May 11, 8:04 AM

Exact Sciences (NASDAQ:EXAS) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

EXAS

News

Sidus Space Enters Pivotal Year Building On A Strong Foundation Of Achievements In 2022

By Benzinga Newsdesk

January 5, 9:33 AM

Sidus Space, Inc. (NASDAQ:SIDU), a Space-as-a-Service company focused on mission-critical hardware manufacturing combined with commercial satellite design, manufacture, launch, and data collection, is pleased to release

SIDU

Baudax Bio Announces 1-for-40 Reverse Stock Split

By Michael Horton

November 30, 5:50 PM

Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for hospital and related settings, today announced that the Company's Board of Directors has approved a 1-for-40 reverse stock

BXRX